Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8285912 | 1.00 | PRCP (0.44) | PRCPDPP7SCN4AFDPSNOS2 | |
| SCHEMBL10067946 | 1.00 | PRCP (0.44) | PRCPDPP7SCN4AFDPSNOS2 | |
| SCHEMBL3957134 | 1.00 | PRCP (0.44) | PRCPDPP7SCN4AFDPSNOS2 | |
| SCHEMBL31048387 | 0.98 | PRCP (0.42) | PRCPDPP7SCN4AFDPSNOS2 | |
| SCHEMBL7299775 | 0.98 | PRCP (0.42) | PRCPDPP7SCN4AFDPSNOS2 | |
| SCHEMBL7298202 | 0.98 | PRCP (0.42) | PRCPDPP7SCN4AFDPSNOS2 | |
| SCHEMBL14296418 | 0.94 | — | — | |
| SCHEMBL878969 | 0.94 | — | — | |
| SCHEMBL805298 | 0.94 | — | — | |
| SCHEMBL15808359 | 0.84 | PRCP (0.45) | PRCPDPP7SCN4AFDPSNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | RECQL, DDX21, DDX41 | PRCP 2978/4885DPP7 2788/4885SCN4A 3606/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | PRCP 1915/4885DPP7 2709/4885SCN4A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.